Yes, Basaglar can and should be increased from 10 units nightly if fasting glucose remains above target.
The standard approach is to titrate Basaglar by increasing the dose by 2 units every 3 days until the fasting plasma glucose (FPG) goal is achieved without hypoglycemia 1.
Initial Dosing Context
The 10 units nightly represents the standard starting dose for basal insulin in type 2 diabetes 2. This conservative initiation dose (or 0.1-0.2 units/kg/day) is designed to minimize hypoglycemia risk while establishing baseline insulin coverage 1.
Evidence-Based Titration Algorithm
Follow this structured approach 1:
- Set an individualized FPG goal (typically 80-130 mg/dL for most adults)
- Increase by 2 units every 3 days to reach FPG goal without hypoglycemia
- Continue titration until fasting glucose consistently meets target
- Reassess every 3-6 months to avoid therapeutic inertia
The FDA label confirms that dosage should be individualized based on metabolic needs and blood glucose monitoring results, with adjustments made under medical supervision 2.
When to Increase
Increase the dose if:
- Fasting glucose remains above the individualized target
- No hypoglycemia is occurring
- The patient is tolerating the current dose well
Titration Ceiling and Overbasalization Warning
Continue increasing up to approximately 0.5 units/kg/day 1. Beyond this point, watch for signs of overbasalization:
- Basal dose exceeding 0.5 units/kg
- High bedtime-to-morning glucose differential
- Elevated postprandial-to-preprandial glucose differential
- Hypoglycemia (aware or unaware)
- High glucose variability
If these signals appear, do not continue escalating basal insulin. Instead, consider adding a GLP-1 receptor agonist (if not already prescribed) or prandial insulin 1, 3.
Hypoglycemia Management
If hypoglycemia occurs during titration:
- Determine the cause
- If no clear reason exists, reduce the dose by 10-20% 1
- Resume titration more cautiously once stable
Key Clinical Pitfall
The most common error is therapeutic inertia—failing to titrate insulin adequately. The 2025 ADA guidelines explicitly emphasize reassessing and modifying therapy regularly every 3-6 months to avoid this 1. Starting at 10 units is appropriate, but staying at 10 units when glucose remains elevated represents suboptimal care.